Aligos Therapeutics, Inc.

As of August 5, 2021, Aligos Therapeutics, Inc. is considered risky and overvalued due to its poor financial metrics and a year-to-date return of -74.92%, significantly underperforming the S&P 500's 12.22%.

As of August 5, 2021, Aligos Therapeutics is classified as "risky" and undervalued with a low Price to Book Value of 0.38 and an EV to EBITDA ratio of 1.07, but its financial health is concerning due to losses and a significant year-to-date stock decline of 81.98%, despite a high ROCE of 478.69% indicating potential for future profitability.

As of June 3, 2025, the trend is mildly bearish due to daily moving averages, while mixed signals from weekly and monthly indicators suggest a cautious outlook with a bearish bias.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral and liver diseases. As of March 2025, it has a market cap of $46.04 million and reported a net profit of $43 million, with no net sales.

As of Jun 18, Aligos Therapeutics, Inc. has a market capitalization of 46.04 million, with net sales of 3.27 million and a net profit of -53.26 million over the last four quarters. The company's shareholder's funds are -28.97 million, and total assets are 71.85 million.